

Markus Ruhnke

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2774941/markus-ruhnke-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

7,027
citations

19
h-index

34
g-index

34
ext. papers

8,045
ext. citations

7.8
avg, IF

4.55
L-index

#	Paper	IF	Citations
30	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1813-21	11.6	3744
29	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. <i>Lancet, The</i> , 2007 , 369, 1519-1527	40	1092
28	Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). <i>Clinical Infectious Diseases</i> , 2007 , 44, 1289-97	11.6	547
27	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases, The</i> , 2019 , 19, e405-e421	25.5	441
26	Improved outcome in central nervous system aspergillosis, using voriconazole treatment. <i>Blood</i> , 2005 , 106, 2641-5	2.2	307
25	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2018 , 97, 197-207	3	104
24	Treatment of invasive fungal infections in cancer patients--updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2014 , 93, 13-32	3	94
23	Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. <i>Mycoses</i> , 2011 , 54, 279-310	5.2	91
22	Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Annals of Hematology</i> , 2014 , 93, 1449-56	3	76
21	Central venous catheter-related infections in hematology and oncology : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2008 , 87, 863-76	3	63
20	Advances in the diagnosis and treatment of fungal infections of the CNS. <i>Lancet Neurology, The</i> , 2018 , 17, 362-372	24.1	62
19	Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. <i>Lancet Oncology, The</i> , 2014 , 15, e606-e619	21.7	59
18	Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2003 , 82 Suppl 2, S133-40	3	58
17	Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. <i>Mycoses</i> , 2007 , 50, 196-200	5.2	54
16	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). <i>Mycoses</i> , 2018 , 61, 796-813	5.2	35
15	Estimated burden of fungal infections in Germany. <i>Mycoses</i> , 2015 , 58 Suppl 5, 22-8	5.2	33
14	Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. <i>Mycoses</i> , 2015 , 58, 58-64	5.2	28

13	Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Mycoses</i> , 2020 , 63, 653-682	5.2	23
12	Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. <i>Therapeutic Advances in Hematology</i> , 2016 , 7, 345-359	5.7	21
11	Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What is <i>Aspergillus</i> ?. <i>Medical Mycology</i> , 2017 , 55, 402-413	3.9	19
10	Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021 , 100, 321-336	3	19
9	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021 , 100, 321-336	3	14
8	Interlaboratory comparison of PCR-based identification of <i>Candida</i> and <i>Aspergillus</i> DNA in spiked blood samples. <i>Mycoses</i> , 2012 , 55, 426-34	5.2	13
7	Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). <i>Mycoses</i> , 2021 , 64, 583-602	5.2	11
6	Prospective evaluation of the SeptiFAST multiplex real-time PCR assay for surveillance and diagnosis of infections in haematological patients after allogeneic stem cell transplantation compared to routine microbiological assays and an in-house real-time PCR method. <i>Mycoses</i> , 2017 , 60, 781-788	5.2	10
5	Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia. <i>Mycoses</i> , 2018 , 61, 331-336	5.2	5
4	Clinical Syndromes: <i>Candida</i> and Candidosis 2019 , 45-75		2
3	First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study. <i>Breast</i> , 2021 , 60, 70-77	3.6	2
2	Infektionen bei Patienten mit hämatologisch-onkologischen Erkrankungen 2020 , 251-279		
1	Infektionen bei Patienten mit hämatologisch-onkologischen Erkrankungen 2017 , 233-262		